secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2026-08-14T20:35:17+00:00
Accession:  0001213900-26-090182
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology Q3 FY2026 revenue $1.5M, LYMPHIR demand accelerates
-------------------------------------------------------------------

- Revenue $1.5M for Q3 ended June 30, 2026 (vs $0 prior year); $7.1M for nine months.
- Net loss $8.9M ($0.08/share) for Q3; $41.1M ($0.42/share) for nine months, incl. $19.7M one-time CMO cancellation charge.
- Institutional vial orders grew 31% sequentially to 926 in Q3; July orders 383 vials, largest month; 44 institutions ordering.
- Cash $16.6M; received $9.7M from warrant exercises and $10M from first tranche of $25M senior secured term loan.
- Appointed Jonathan Peri as independent director; commercial team expanded to 29 professionals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026090182/0001213900-26-090182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026090182/ea0302226-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-090182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer